Skip to main content

Clarient, Acorn Team Up on Tumor Molecular Testing

NEW YORK (GenomeWeb News) – GE Healthcare company Clarient and Acorn Research today announced a collaboration targeting the molecular testing of tumor samples.

The collaboration, the terms of which were not disclosed, brings together Clarient's expertise in cancer diagnostics and Acorn's oncology network and advanced bioinformatics platform, they said.

The firms will create standardized testing protocols across the Acorn network of oncology community practices and hospitals "with treatment guidelines and clinical trial opportunities," in the hope of delivering individualized targeted treatments based on specific genetic markers. A system for collecting tumor specific biomarker data when patients are initially diagnosed with cancer will also be established.

The collaboration, the firms said, will enable the matching of biomarker data with outcomes data for clinical trials and clinical practice to identify new prognostic biomarkers and biomarker-specific treatments.

Discovering new biomarkers that could lead to the treatment of cancer on an individualized basis "has the potential to improve mortality rates, enhance patient quality of life, and reduce the cost of burden on cancer treatment to both patients and payers," Ron Andrews, CEO of Clarient, said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.